Cipla inks pact with Hetero to launch Darbepoetin Alfa in India: Report

19 Jun 2014 Evaluate

Cipla has reportedly entered into agreement with Hetero to launch Darbepoetin Alfa in India. Darbepoetin Alfa is a synthetic form of erythropoietin, clinically proven to stimulate erythropoiesis (increased hemoglobin levels) for patients with anemia due to chronic kidney disease.

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.

Cipla Share Price

1320.70 7.85 (0.60%)
28-Jan-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1627.75
Dr. Reddys Lab 1234.95
Cipla 1320.70
Zydus Lifesciences 889.60
Lupin 2137.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×